Skip to main content
PMC home page
Public Health Reports logoLink to Public Health Reports
. 1992 Jul-Aug;107(4):461–468.

HIV infection treatment costs under Medicaid in Michigan.

D J Solomon 1, A J Hogan 1
PMCID: PMC1403678  PMID: 1641444

Abstract

The Michigan Medicaid Program payment records generated in the period 1985-89 by 783 persons were analyzed for services related to human immunodeficiency virus (HIV) infection. Other data from death records and the Michigan AIDS Surveillance Registry were available for a subset of those persons. The average monthly payment in 1989 dollars for HIV-related services was $1,302.57. Services determined to be unrelated to HIV infection accounted for 12.5 percent of the total amount for health care received and another 2.5 percent was questionable. The average monthly expenditure for men was roughly twice that for women. The discrepancy did not exist among persons identified in the AIDS Surveillance Registry. Sex differences ceased to exist when Medicaid eligibility (disability versus Aid to Families with Dependent Children) was controlled for by analysis of variance. There were no significant differences between payments to those infected through male-to-male sexual contact and those infected through intravenous drug use. Payments for HIV treatments rose with age to about 40 years, and declined slightly among older adults. The sharpest rise was for those ages 19-25 years and 26-35 years. Large sex differences existed among those who received zidovudine (AZT), 61.4 percent of the men and 19.1 percent of the women. Controlling for Medicaid eligibility moderated those differences, but they remained statistically significant. Differences in zidovudine usage were not found between men and women in the subset identified in the AIDS Surveillance Registry nor among persons infected through male-to-male sexual contact and intravenous drug use.

Full text

PDF

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Chu S. Y., Buehler J. W., Berkelman R. L. Impact of the human immunodeficiency virus epidemic on mortality in women of reproductive age, United States. JAMA. 1990 Jul 11;264(2):225–229. [PubMed] [Google Scholar]
  2. Friedland G. H. Early treatment for HIV: the time has come. N Engl J Med. 1990 Apr 5;322(14):1000–1002. doi: 10.1056/NEJM199004053221409. [DOI] [PubMed] [Google Scholar]
  3. Guinan M. E., Hardy A. Epidemiology of AIDS in women in the United States. 1981 through 1986. JAMA. 1987 Apr 17;257(15):2039–2042. [PubMed] [Google Scholar]
  4. Hellinger F. J. Forecasting the medical care costs of the HIV epidemic: 1991-1994. Inquiry. 1991 Fall;28(3):213–225. [PubMed] [Google Scholar]
  5. Hellinger F. J. Updated forecasts of the costs of medical care for persons with AIDS, 1989-93. Public Health Rep. 1990 Jan-Feb;105(1):1–12. [PMC free article] [PubMed] [Google Scholar]
  6. Hogan A. J., Soloman D. J., Bouknight R. R., Soloman C. T. Under-utilization of medical care services by HIV-infected women? Some preliminary results from the Michigan Medicaid Program. AIDS. 1991 Mar;5(3):338–339. [PubMed] [Google Scholar]
  7. Lemp G. F., Payne S. F., Neal D., Temelso T., Rutherford G. W. Survival trends for patients with AIDS. JAMA. 1990 Jan 19;263(3):402–406. [PubMed] [Google Scholar]
  8. Moore R. D., Hidalgo J., Sugland B. W., Chaisson R. E. Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med. 1991 May 16;324(20):1412–1416. doi: 10.1056/NEJM199105163242006. [DOI] [PubMed] [Google Scholar]
  9. Quinn T. C. The epidemiology of the human immunodeficiency virus. Ann Emerg Med. 1990 Mar;19(3):225–232. doi: 10.1016/s0196-0644(05)82035-9. [DOI] [PubMed] [Google Scholar]
  10. Scitovsky A. A., Cline M. W., Abrams D. I. Effects of the use of AZT on the medical care costs of persons with AIDS in the first 12 months. J Acquir Immune Defic Syndr. 1990;3(9):904–912. [PubMed] [Google Scholar]
  11. Scitovsky A. A., Cline M., Lee P. R. Medical care costs of patients with AIDS in San Francisco. JAMA. 1986 Dec 12;256(22):3103–3106. [PubMed] [Google Scholar]
  12. Solomon D. J., Hogan A. J., Bouknight R. R., Solomon C. T. Analysis of Michigan Medicaid costs to treat HIV infection. Public Health Rep. 1989 Sep-Oct;104(5):416–424. [PMC free article] [PubMed] [Google Scholar]
  13. Solomon P. J., Wilson S. R., Swanson C. E., Cooper D. A. Effect of zidovudine on survival of patients with AIDS in Australia. Med J Aust. 1990 Sep 3;153(5):254–257. doi: 10.5694/j.1326-5377.1990.tb136895.x. [DOI] [PubMed] [Google Scholar]
  14. Stein M. D., Piette J., Mor V., Wachtel T. J., Fleishman J., Mayer K. H., Carpenter C. C. Differences in access to zidovudine (AZT) among symptomatic HIV-infected persons. J Gen Intern Med. 1991 Jan-Feb;6(1):35–40. doi: 10.1007/BF02599388. [DOI] [PubMed] [Google Scholar]
  15. Wu A. W., Mathews W. C., Brysk L. T., Atkinson J. H., Grant I., Abramson I., Kennedy C. J., McCutchan J. A., Spector S. A., Richman D. D. Quality of life in a placebo-controlled trial of zidovudine in patients with AIDS and AIDS-related complex. J Acquir Immune Defic Syndr. 1990;3(7):683–690. [PubMed] [Google Scholar]

Articles from Public Health Reports are provided here courtesy of SAGE Publications

RESOURCES